NMPA Approves 323 Medical Devices in June 2026

On July 15, 2026, China's National Medical Products Administration (NMPA) officially announced the approval of 323 medical device products for the month of June 2026.

Breakdown by Category:

Domestic Class III Medical Devices: 282 products

Imported Class III Medical Devices: 30 products

Imported Class II Medical Devices: 10 products

Hong Kong, Macao & Taiwan Medical Devices: 1 product

Notable Approvals Include:

High-Value Implants & Interventional Devices:

Trifocal Intraocular Lens (Henan Semai Shi Biotechnology)

Adjustable-curvature Pulmonary Artery Thrombectomy Stent System (Shanghai Xuanyu Medical)

Interventional Left Ventricular Assist Device (Fengkaili Medical)

Bioresorbable Coronary Sirolimus-Eluting Stent System (Shanghai Baixin'an Biotechnology)

Advanced Imaging Systems:

MRI Systems, CT Systems, and Color Doppler Ultrasound Systems from multiple domestic and international manufacturersSurgical & Therapeutic Equipment:Ultrasonic Soft Tissue Surgical Knives, Plasma Surgical Electrodes, and various energy-based surgical platforms

IVD Products:

Multiple nucleic acid detection kits for influenza, hepatitis B, HPV, and genetic mutation testing

Industry Insight:

This month's approvals showcase China's continued momentum in high-end medical device innovation—particularly in cardiovascular implants, ophthalmic devices, orthopedic materials, and molecular diagnostics. Domestic manufacturers are demonstrating increasing competitiveness in Class III devices, which now account for over 87% of all approvals.